The US Food and Drug Administration's drug center plans to issue 102 new and revised draft guidances during calendar year 2016, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and abbreviated new drug application (ANDA) refuse-to-receive standards.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?